Cellectar Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

FAIR VALUE (Tables)

FAIR VALUE (Tables)

12 Months Ended

Dec. 31, 2013

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

The following tables set forth the Company’s financial instruments carried at fair value using the lowest level of input applicable to each financial instrument as of December 31, 2013 and December 31, 2012:

	December 31, 2013
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
Legacy Warrants	$	—	$	4,363	$	—	$	4,363
February 2013 Public Offering Warrants		—		—		3,355,000		3,355,000
Total	$	—	$	4,363	$	3,355,000	$	3,359,363

	December 31, 2012
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
Legacy Warrants	$	—	$	13,304	$	—	$	13,304

Schedule Of Changes In Fair Value Warrants Classified Level Three [Table Text Block]

The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy.

	December 31, 2013		December 31, 2012

Beginning balance	$	—	$	—
Fair value of warrants issued in connection with February 2013 public offering		5,720,000		—
Gain on derivatives resulting from change in fair value		(2,365,000)		—
Warrants	$	3,355,000	$	—

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References + Details